---
slug: semaglutide-metformin
title: "semaglutide metformin"
kind: standard
status: published
hash: d0028e678d0f7be122ba93a18d8fed3569f293dd0218c52339dd2039f82e9e20
created: 2026-06-29T17:31:34.058Z
updated: 2026-10-08T11:49:33.889Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# semaglutide metformin

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:32:34.856Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease](https://pubmed.ncbi.nlm.nih.gov/39700591/) — “The combination of semaglutide and metformin significantly improves liver inflammation, fibrosis, and beta-cell function in patients with T2DM and NAFLD” (sha256 c5445ae4e12ac3d6)
2. [Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial](https://pubmed.ncbi.nlm.nih.gov/40713699/) — “Compared to MET monotherapy, combination therapy with semaglutide and MET significantly reduced body weight, improved insulin resistance, decreased ...” (sha256 a13cdddab60db8d2)
3. [Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study](https://pubmed.ncbi.nlm.nih.gov/39796271/) — “The results indicate that combining 1 mM metformin with either 10 nM semaglutide or 10 nM tirzepatide significantly enhances the effects of 10 nM semaglutide” (sha256 1e2507774451c57b)
4. [Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)](https://pubmed.ncbi.nlm.nih.gov/42026662/) — “Generic semaglutide demonstrated non-inferior efficacy and comparable safety to innovator Semaglutide in Indian adults with T2DM inadequately controlled on metformin” (sha256 ff542986315bd3ed)
5. [Effect of semaglutide with metformin for weight loss and ...](https://pubmed.ncbi.nlm.nih.gov/41421448/) — “In this study , we demonstrated a significant efficacy of combined treatment with subcutaneous semaglutide and metformin in effective weight reduction and ...” (sha256 4ce68cd85821e29b)
6. [Semaglutide Plus Low-Dose Metformin Combination ...](https://pubmed.ncbi.nlm.nih.gov/41893436/) — “At 5 months after initiation of the combination therapy, blood tests showed metabolic improvements, including improvement of prediabetes (0.3- ...” (sha256 68ae2de162c1b3aa)
7. [Semaglutide Plus Metformin Versus ...](https://pubmed.ncbi.nlm.nih.gov/40227520/) — “38.7% (12/31) of patients in the monotherapy group achieved the primary outcome of weight loss ≥ 5% from baseline vs. 61.29% (19/31) in the ...” (sha256 d442d66586ed742d)
8. [Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial](https://pubmed.ncbi.nlm.nih.gov/41765029/) — “This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individuals with type 2 diabetes inadequately controlled with metformin.” (sha256 2e94ad3c48b93218)
9. [Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study](https://pubmed.ncbi.nlm.nih.gov/42251859/) — “Participants aged 18 years or older with inadequately controlled type 2 diabetes (HbA1c 7·0-10·5% [53-91 mmol/mol]) receiving metformin with or without an SGLT2 inhibitor, and a BMI of 25 kg/m 2 or more” (sha256 e05188cb8b787e50)
10. [Semaglutide Injection in Indian Patients With Type 2 Diabetes Inadequately Controlled on Metformin](https://pubmed.ncbi.nlm.nih.gov/42219226/) — “... metformin therapy and diet & exercise control were randomised (1:1) to receive subcutaneous injections of Test semaglutide or Reference semaglutide once ...” (sha256 7ba8cd10f039894d)
11. [Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a systematic review and network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/41715123/) — “2.4 mg of semaglutide SC and 15 mg of tirzepatide were the best option among the included interventions considering favorable glucose and BMI control.” (sha256 d9d5fcfd891ace85)